8-K: SCWorx Corp. Faces Nasdaq Delisting, Seeks Reconsideration

SCWorx Corp. has received a Nasdaq delisting decision but is seeking reconsideration after a private placement aimed at curing a public float deficiency.

Summary

• SCWorx Corp. received a decision from the Nasdaq Hearings Panel to delist its common stock.
• This decision was made despite the company completing a private placement on September 16, 2026, which it believes has cured the deficiency in publicly held shares.
• The company has formally requested the Panel reconsider its decision, citing a mistake of material fact as the decision did not account for the completed private placement.
• SCWorx must still demonstrate a closing bid price of at least $1.00 per share for 10 consecutive trading days by October 5, 2026, to regain compliance with Nasdaq's Bid Price Rule.
• The common stock will continue to be quoted on the OTCQB Venture Market.
• The company has extended the period for private placement investors to exercise their termination rights until October 15, 2026, due to the delisting uncertainty.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the ongoing delisting concerns and the potential for significant financial repercussions if a capital raise is unwound.

Positives

• Completed a private placement of 350,000 shares and warrants, which the company believes has cured the deficiency in publicly held shares.
• Successfully met Nasdaq's minimum bid price requirement for 20 consecutive trading days ending August 31, 2026, after a 1-for-12 reverse stock split.

Negatives

• Received a Nasdaq Hearings Panel decision to delist the common stock.
• The Panel was not persuaded that the company's compliance plan presented a reasonable likelihood of regaining compliance by the October 5, 2026 deadline.
• If all private placement investors exercise their termination rights, the company would have to return $938,000 and cancel shares and warrants issued in the placement, further reducing publicly held shares.

Risks

• The Nasdaq Hearings Panel may not grant the request for reconsideration.
• The Nasdaq Listing and Hearing Review Council may not reverse or modify the Panel's delisting decision.
• The company may fail to evidence a closing bid price of at least $1.00 per share for 10 consecutive trading days by October 5, 2026.
• Nasdaq may not agree that the company has cured the publicly held shares deficiency.
• Purchasers in the private placement may exercise their termination rights, leading to a return of $938,000 and cancellation of issued securities.
• If compliance is not regained, the common stock will be delisted from Nasdaq.

Future Outlook

The company is actively seeking to regain compliance with Nasdaq's listing requirements, including curing a deficiency in publicly held shares and meeting a minimum bid price. There is uncertainty regarding the outcome of its request for reconsideration and its ability to meet the deadlines.

Management Comments

• The Company believes that it has more than 500,000 Publicly Held Shares and has cured its deficiency under Nasdaqs Publicly Held Shares Rule.
• The Company formally requested that the Panel reconsider its decision on the grounds that it was based on a mistake of material fact.
• The Company has determined to treat the Panel Decision as a determination letter delisting the Common Stock for purposes of Section 4.20 of the Purchase Agreement.
• The Company has notified the Purchasers that it will treat any termination notice under Section 4.20 delivered on or before October 15, 2026, as timely delivered.

Industry Context

StockSavvy.ai notes that maintaining Nasdaq listing is crucial for many smaller companies to access capital and enhance visibility. Companies often face challenges with listing requirements, especially after significant corporate actions like reverse stock splits, which can impact share price and float.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq could negatively impact liquidity and share price. The outcome of the reconsideration and bid price compliance is critical.
• Investors in the private placement: Face uncertainty regarding their investment, with a potential termination right to recover their capital if delisting occurs or trading does not resume by a certain date.

Next Steps

• Await the Nasdaq Hearings Panel's decision on the request for reconsideration.
• Continue efforts to evidence a closing bid price of at least $1.00 per share for 10 consecutive trading days by October 5, 2026.
• Potentially request review by the Nasdaq Listing and Hearing Review Council if necessary.
• Monitor the exercise of termination rights by private placement investors.

Key Dates

Recommendation

The company is in a precarious position with a delisting decision from Nasdaq, although it is actively seeking reconsideration and has taken steps to address listing requirements. The outcome remains highly uncertain, making a 'hold' recommendation appropriate until clarity emerges on Nasdaq compliance and the potential unwinding of the recent capital raise.

Keywords

Nasdaq delisting, Publicly Held Shares Rule, Bid Price Rule, Private Placement, Reconsideration Request, OTCQB Venture Market, Compliance Plan, Reverse Stock Split